Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.03 is 47% below its 5-year average of 15.14, near the low end of its 5-year range (8.03–32.65).
As of the fiscal period ended Tuesday, June 30, 2026. 8.57% below its 12-month average of 8.79.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.03.
QUICK RATIO (ACID-TEST)
8.03
QUICK RATIO (ACID-TEST) AVG TTM
8.79
QUICK RATIO (ACID-TEST) AVG 3Y
14.49
QUICK RATIO (ACID-TEST) AVG 5Y
15.14
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.57%
CURRENT VS 3Y AVG
-44.56%
CURRENT VS 5Y AVG
-46.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 792 covered companies
CURRENT VS SECTOR MEDIAN
+144.91%
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$665.51M
Quick Ratio (Acid-Test)
8.03
TTM Avg
8.79
3Y Avg
14.49
5Y Avg
15.14
Market Cap
$668.53M
Quick Ratio (Acid-Test)
4.79
TTM Avg
3.80
3Y Avg
3.38
5Y Avg
3.21
Market Cap
$660.39M
Quick Ratio (Acid-Test)
1.15
TTM Avg
1.35
3Y Avg
1.35
5Y Avg
1.35
Market Cap
$673.15M
Quick Ratio (Acid-Test)
10.97
TTM Avg
8.63
3Y Avg
10.75
5Y Avg
10.66
Market Cap
$674.61M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$681.76M
Quick Ratio (Acid-Test)
13.82
TTM Avg
5.67
3Y Avg
7.51
5Y Avg
7.66
Market Cap
$688.65M
Quick Ratio (Acid-Test)
14.20
TTM Avg
2.59
3Y Avg
2.42
5Y Avg
2.06
Market Cap
$632.99M
Quick Ratio (Acid-Test)
2.55
TTM Avg
2.67
3Y Avg
4.11
5Y Avg
5.17
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $665.51M | 8.03 | 8.79 | 14.49 | 15.14 |
| MiMedx Group, Inc. (MDXG)vs › | $668.53M | 4.79 | 3.80 | 3.38 | 3.21 |
| Starling Oncology, Inc. (STLN)vs › | $660.39M | 1.15 | 1.35 | 1.35 | 1.35 |
| Helus Pharma Inc. (HELP)vs › | $673.15M | 10.97 | 8.63 | 10.75 | 10.66 |
| Annexon, Inc. (ANNX)vs › | $674.61M | 5.53 | 8.02 | 10.47 | 14.43 |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | 13.82 | 5.67 | 7.51 | 7.66 |
| OmniAb, Inc. (OABI)vs › | $649.48M | 4.80 | 4.27 | 4.36 | 3.29 |
| Anteris Technologies Global Corp. (AVR)vs › | $688.65M | 14.20 | 2.59 | 2.42 | 2.06 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $632.99M | 2.55 | 2.67 | 4.11 | 5.17 |
| Aura Biosciences, Inc. (AURA)vs › | $632.00M | 16.82 | 9.46 | 14.12 | 14.05 |
Quick Ratio
8.03
Excludes inventory
Current Ratio
8.03
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.03 |
| 2026-03-31 | 9.34 |
| 2025-12-31 | 9.39 |
| 2025-09-30 | 8.42 |
| 2025-06-30 | 8.75 |
| 2025-03-31 | 12.36 |
| 2024-12-31 | 14.92 |
| 2024-09-30 | 17.33 |
| 2024-06-30 | 28.48 |
| 2024-03-31 | 32.65 |
| 2023-12-31 | 15.65 |
| 2023-09-30 | 18.07 |
| 2023-06-30 | 23.11 |
| 2023-03-31 | 18.36 |
| 2022-12-31 | 14.02 |
| 2022-09-30 | 17.14 |
| 2022-06-30 | 17.20 |
| 2022-03-31 | 20.10 |
| 2021-12-31 | 15.69 |
| 2021-09-30 | 14.57 |
| 2021-06-30 | 25.20 |
| 2021-03-31 | 19.01 |
| 2020-12-31 | 16.88 |
| 2020-09-30 | 6.48 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 4.05 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 8.77 |
| 2019-03-31 | 8.77 |
| 2018-12-31 | 11.68 |
| 2018-09-30 | 11.68 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
